Michael R. Horsman is currently Professor of Experimental Radiotherapy at Aarhus University and works in the Department of Experimental Oncology (DECO), Aarhus University Hospital, Denmark. He obtained a BSc with Honours in Human Biology from Oxford Polytechnic in 1977, a PhD in Radiation Biology from the University of London in 1981, and a Doctor of Medical Science from Aarhus University in 1996. His first research appointment was at the Department of Therapeutic Radiology, Stanford University, California where he worked from 1981 to 1986, before joining DECO in 1987. He has published extensively on radiation related topics. His major radiobiological contribution was being the first to discover that nicotinamide prevented acute hypoxia, and the first to suggest and demonstrate the potential of combining that drug with therapies that targeted chronic hypoxia. Those studies played a significant role in developing clinical trials in patients with head & neck (ARCON) and bladder (BCON) cancer. His current research areas focus on the tumour microenvironment and vasculature. He has received several awards, including the Lund Science Award (1988), the ESHO-BSD Award (2011), and the Order of St. John Fellowship Anniversary Silver Medal Award (2013). He has also been involved in numerous scientific conferences as a co-organizer, session chairperson, or invited speaker. In addition, he has been an Associate Editor or on the Editorial board of several International Scientific Journals, and a supervisor and examiner for a number of different Universities worldwide.